Barclays Maintains Overweight on Legend Biotech, Raises Price Target to $94
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Gena Wang has maintained an Overweight rating on Legend Biotech (NASDAQ:LEGN) and increased the price target from $93 to $94.
January 24, 2024 | 9:08 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Barclays has reaffirmed Legend Biotech's Overweight rating and raised the price target from $93 to $94, indicating a positive outlook on the stock.
The increase in price target by Barclays reflects a positive assessment of Legend Biotech's prospects, which could lead to increased investor confidence and a potential short-term rise in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100